Amid the expiration of pharmaceutical patents, discussions are underway regarding the substantial reduction of drug 토토 사이트 바카라 through international rate references. On November 6th, the Health Insurance Review and Assessment Service (HIRA) initiated discussions with the pharmaceutical sector to reevaluate international drug price comparisons. Responding to a recent inquiry, HIRA indicated that they have refined the criteria for referencing foreign drug 토토 사이트 바카라 and are currently formulating plans for reevaluating the international 토토 사이트 바카라 of registered pharmaceuticals.
In a statement, HIRA outlined, "Following consultations with industry stakeholders, we intend to finalize the plan within this year, with the reassessment slated to commence annually starting in 2024." They further explained, "By managing drug 토토 사이트 바카라 for products that are significantly higher compared to other countries, we aim to ensure the financial sustainability of health insurance."
The industry is optimistic that the reassessment of drug reimbursement appropriateness and the determination of maximum allowable 토토 사이트 바카라 for re-registered drugs will pave the way for the reassessment of international drug 토토 사이트 바카라. Currently, discussions are necessary to establish evaluation criteria, including the drugs to be considered, the methodology for price comparisons, and the setting of comparative 토토 사이트 바카라.
However, the industry is notably apprehensive about the impending reassessment of international drug 토토 사이트 바카라, primarily due to its potential impact on the sector, including the evaluation criteria. When the industry conducted simulations on the effects of applying average 토토 사이트 바카라 to drugs for conditions such as hypertension, hyperlipidemia, and diabetes, the results indicated a potential revenue loss of approximately .6 million.
During a recent seminar held by the law firm Sejong, which focused on addressing the reassessment of international drug 토토 사이트 바카라, product-specific simulations revealed that implementing A8 adjusted minimum 토토 사이트 바카라 could result in substantial price reductions for hyperlipidemia medications, estimated at up to 93.3%. This would decrease annual claims from 4.3 million to .4 million. Similarly, hyperlipidemia R medications could see an 84.6% reduction, reducing annual claims from 3.8 million to .5 million. However, these criteria are expected to pose significant challenges for pharmaceutical companies, prompting consideration of alternative models, such as setting A8 minimum 토토 사이트 바카라 based on the average of the three lowest-priced countries or a weighted average of A8 country minimum 토토 사이트 바카라.
The pharmaceutical industry is apprehensive that the reassessment of international drug 토토 사이트 바카라 may lead to revenue losses, potentially resulting in downsizing for small pharmaceutical companies, staff reductions in both Korean and international firms, and setbacks in drug development within Korea.
Some industry insiders question the rationale of using a specific point in international drug 토토 사이트 바카라 as the basis for determining the extent of domestic drug price reductions within the current reassessment system. Another insider emphasized the importance of first reviewing whether existing post-management mechanisms align with their intended purposes and objectives. They also stressed the significance of effective communication and the incorporation of industry perspectives in any reassessment process.